Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis

Nearly 50% of patients with systemic lupus erythematosus (SLE) will develop lupus nephritis (LN). Current treatment regimens for LN are suboptimal as the majority of patients fail to achieve complete renal response after several months of treatment and there are high rates of relapse. We report outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Baum, Rebecca, Geetha, Duruvu, Fatola, Ayotola, Timlin, Homa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256255/
https://www.ncbi.nlm.nih.gov/pubmed/37303434
http://dx.doi.org/10.7759/cureus.38848
_version_ 1785057063701839872
author Baum, Rebecca
Geetha, Duruvu
Fatola, Ayotola
Timlin, Homa
author_facet Baum, Rebecca
Geetha, Duruvu
Fatola, Ayotola
Timlin, Homa
author_sort Baum, Rebecca
collection PubMed
description Nearly 50% of patients with systemic lupus erythematosus (SLE) will develop lupus nephritis (LN). Current treatment regimens for LN are suboptimal as the majority of patients fail to achieve complete renal response after several months of treatment and there are high rates of relapse. We report outcomes in four LN patients who were treated with both voclosporin and belimumab. These patients had no serious infections, and we were able to taper glucocorticoids and reduce proteinuria.
format Online
Article
Text
id pubmed-10256255
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102562552023-06-10 Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis Baum, Rebecca Geetha, Duruvu Fatola, Ayotola Timlin, Homa Cureus Internal Medicine Nearly 50% of patients with systemic lupus erythematosus (SLE) will develop lupus nephritis (LN). Current treatment regimens for LN are suboptimal as the majority of patients fail to achieve complete renal response after several months of treatment and there are high rates of relapse. We report outcomes in four LN patients who were treated with both voclosporin and belimumab. These patients had no serious infections, and we were able to taper glucocorticoids and reduce proteinuria. Cureus 2023-05-10 /pmc/articles/PMC10256255/ /pubmed/37303434 http://dx.doi.org/10.7759/cureus.38848 Text en Copyright © 2023, Baum et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Baum, Rebecca
Geetha, Duruvu
Fatola, Ayotola
Timlin, Homa
Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
title Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
title_full Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
title_fullStr Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
title_full_unstemmed Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
title_short Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
title_sort treatment using both voclosporin and belimumab in four patients with lupus nephritis
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256255/
https://www.ncbi.nlm.nih.gov/pubmed/37303434
http://dx.doi.org/10.7759/cureus.38848
work_keys_str_mv AT baumrebecca treatmentusingbothvoclosporinandbelimumabinfourpatientswithlupusnephritis
AT geethaduruvu treatmentusingbothvoclosporinandbelimumabinfourpatientswithlupusnephritis
AT fatolaayotola treatmentusingbothvoclosporinandbelimumabinfourpatientswithlupusnephritis
AT timlinhoma treatmentusingbothvoclosporinandbelimumabinfourpatientswithlupusnephritis

Ejemplares similares